Yoshitaka Tanaka

Nissui Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of culture media and diagnostic reagents for medical institutions, research organizations, and food industries. It operates through the Clinical Diagnostics and Pharmaceuticals segment. The Clinical Diagnostics segment provides reagents and instruments for microbiological and immunological tests. The Pharmaceuticals segment offers over-the-counter pharmaceutical products and health food supplements. The company was founded on April 6, 1935 and is headquartered in Tokyo, Japan.

CellGenTech, Inc. engages in the research and development of drugs for new gene therapy and regenerative medicine. It offers adipocyte-based medicine, technology for the development of gene/cell therapies. It also provides protein supplemental therapy solutions in the areas of hereditary diseases; orphan diseases; intractable diseases, such as lysosome and hemophilia; diabetics; arteriosclerotic diseases, and cancer or degenerative neuropathies. The company was founded by Masayuki Aso on October 20, 2003 and is headquartered in Chiba, Japan.